Related Articles
Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial
A β-tubulin 5-derived peptide induces cytotoxic T lymphocytes restricted to the HLA-A24 allele in prostate cancer patients
Capability of SART3109-118 peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles
Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens
A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients